These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38788718)

  • 1. Molecular subtypes of neuroendocrine carcinomas: A cross-tissue classification framework based on five transcriptional regulators.
    Wang Z; Liu C; Zheng S; Yao Y; Wang S; Wang X; Yin E; Zeng Q; Zhang C; Zhang G; Tang W; Zheng B; Xue L; Wang Z; Feng X; Wang Y; Ying J; Xue Q; Sun N; He J
    Cancer Cell; 2024 Jun; 42(6):1106-1125.e8. PubMed ID: 38788718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study.
    Megyesfalvi Z; Barany N; Lantos A; Valko Z; Pipek O; Lang C; Schwendenwein A; Oberndorfer F; Paku S; Ferencz B; Dezso K; Fillinger J; Lohinai Z; Moldvay J; Galffy G; Szeitz B; Rezeli M; Rivard C; Hirsch FR; Brcic L; Popper H; Kern I; Kovacevic M; Skarda J; Mittak M; Marko-Varga G; Bogos K; Renyi-Vamos F; Hoda MA; Klikovits T; Hoetzenecker K; Schelch K; Laszlo V; Dome B
    J Pathol; 2022 Aug; 257(5):674-686. PubMed ID: 35489038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of Small Cell Lung Cancer Molecular Subtyping Markers to Small Cell Neuroendocrine Carcinoma of the Cervix: NEUROD1 as a Poor Prognostic Factor.
    Kim G; Kim M; Nam EJ; Lee JY; Park E
    Am J Surg Pathol; 2024 Mar; 48(3):364-372. PubMed ID: 37981832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization.
    Baine MK; Hsieh MS; Lai WV; Egger JV; Jungbluth AA; Daneshbod Y; Beras A; Spencer R; Lopardo J; Bodd F; Montecalvo J; Sauter JL; Chang JC; Buonocore DJ; Travis WD; Sen T; Poirier JT; Rudin CM; Rekhtman N
    J Thorac Oncol; 2020 Dec; 15(12):1823-1835. PubMed ID: 33011388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Classification of Extrapulmonary Neuroendocrine Carcinomas With Emphasis on POU2F3-positive Tuft Cell Carcinoma.
    Koh J; Kim H; Moon KC; Lee C; Lee K; Ryu HS; Jung KC; Jeon YK
    Am J Surg Pathol; 2023 Feb; 47(2):183-193. PubMed ID: 36253891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer.
    Cejas P; Xie Y; Font-Tello A; Lim K; Syamala S; Qiu X; Tewari AK; Shah N; Nguyen HM; Patel RA; Brown L; Coleman I; Hackeng WM; Brosens L; Dreijerink KMA; Ellis L; Alaiwi SA; Seo JH; Baca S; Beltran H; Khani F; Pomerantz M; Dall'Agnese A; Crowdis J; Van Allen EM; Bellmunt J; Morrisey C; Nelson PS; DeCaprio J; Farago A; Dyson N; Drapkin B; Liu XS; Freedman M; Haffner MC; Corey E; Brown M; Long HW
    Nat Commun; 2021 Oct; 12(1):5775. PubMed ID: 34599169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers.
    Qu S; Fetsch P; Thomas A; Pommier Y; Schrump DS; Miettinen MM; Chen H
    J Thorac Oncol; 2022 Jan; 17(1):141-153. PubMed ID: 34534680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer.
    Feng M; Matoso A; Epstein G; Fong M; Park YH; Gabrielson A; Patel S; Czerniak B; Compérat E; Hoffman-Censits J; Kates M; Kim S; McConkey D; Choi W
    Eur Urol; 2024 Jun; 85(6):523-526. PubMed ID: 37380560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell/Neuroendocrine Carcinoma with Prognostic Implications.
    Akbulut D; Whiting K; Teo MY; Tallman JE; Gokturk Ozcan G; Basar M; Jia L; Chen JF; Sarungbam J; Chen YB; Gopalan A; Fine SW; Tickoo SK; Mehra R; Baine M; Bochner BH; Pietzak EJ; Bajorin DF; Rosenberg JE; Iyer G; Solit DB; Reuter VE; Rekhtman N; Ostrovnaya I; Al-Ahmadie H
    Mod Pathol; 2024 Jul; ():100557. PubMed ID: 38964503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract.
    Wu H; Yu Z; Liu Y; Guo L; Teng L; Guo L; Liang L; Wang J; Gao J; Li R; Yang L; Nie X; Su D; Liang Z
    Cancer Commun (Lond); 2022 Dec; 42(12):1367-1386. PubMed ID: 36264285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ASCL1 regulates super-enhancer-associated miRNAs to define molecular subtypes of small cell lung cancer.
    Miyakawa K; Miyashita N; Horie M; Terasaki Y; Tanaka H; Urushiyama H; Fukuda K; Okabe Y; Ishii T; Kuwahara N; Suzuki HI; Nagase T; Saito A
    Cancer Sci; 2022 Nov; 113(11):3932-3946. PubMed ID: 35789143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Subtypes of High-Grade Neuroendocrine Carcinoma (HGNEC): What is YAP1-Positive HGNEC?
    Kawai H; Matsuoka R; Ito T; Matsubara D
    Front Biosci (Landmark Ed); 2022 Mar; 27(3):108. PubMed ID: 35345340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies.
    Ng J; Cai L; Girard L; Prall OWJ; Rajan N; Khoo C; Batrouney A; Byrne DJ; Boyd DK; Kersbergen AJ; Christie M; Minna JD; Burr ML; Sutherland KD
    Clin Cancer Res; 2024 May; 30(9):1846-1858. PubMed ID: 38180245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin.
    Matsui S; Haruki T; Oshima Y; Kidokoro Y; Sakabe T; Umekita Y; Nakamura H
    Thorac Cancer; 2022 Apr; 13(8):1184-1192. PubMed ID: 35278040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular features and evolutionary trajectory of ASCL1
    Zhang X; Wang H; Liu W; Xiao Z; Ma Z; Zhang Z; Gong W; Chen J; Liu Z
    Br J Cancer; 2023 Mar; 128(5):748-759. PubMed ID: 36517551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concordance of ASCL1, NEUROD1 and POU2F3 transcription factor-based subtype assignment in paired tumour samples from small cell lung carcinoma.
    Denize T; Meador CB; Rider AB; Ganci ML; Barth JL; Kem M; Mino-Kenudson M; Hung YP
    Histopathology; 2023 Dec; 83(6):912-924. PubMed ID: 37644667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in histogenesis research of lung neuroendocrine cancers: Evidence obtained from functional analyses of primitive neural/neuroendocrine cell-specific transcription factors.
    Yazawa T
    Pathol Int; 2015 Jun; 65(6):277-85. PubMed ID: 25708144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Subtypes of Extra-pulmonary Neuroendocrine Carcinomas Identified by the Expression of Neuroendocrine Lineage-Specific Transcription Factors.
    Metovic J; La Salvia A; Rapa I; Napoli F; Birocco N; Pia Bizzi M; Garcia-Carbonero R; Ciuffreda L; Scagliotti G; Papotti M; Volante M
    Endocr Pathol; 2022 Sep; 33(3):388-399. PubMed ID: 35608806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. REST Inactivation and Coexpression of ASCL1 and POU3F4 Are Necessary for the Complete Transformation of RB1/TP53-Inactivated Lung Adenocarcinoma into Neuroendocrine Carcinoma.
    Masawa M; Sato-Yazawa H; Kashiwagi K; Ishii J; Miyata-Hiramatsu C; Iwamoto M; Kohno K; Miyazawa T; Onozaki M; Noda S; Shimizu Y; Niho S; Yazawa T
    Am J Pathol; 2022 Jun; 192(6):847-861. PubMed ID: 35367201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An integrative epigenomic approach identifies ELF3 as an oncogenic regulator in ASCL1-positive neuroendocrine carcinoma.
    Horie M; Tanaka H; Suzuki M; Sato Y; Takata S; Takai E; Miyashita N; Saito A; Nakatani Y; Yachida S
    Cancer Sci; 2023 Jun; 114(6):2596-2608. PubMed ID: 36840413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.